Evolutionary Genomics Valuation
| FNAM Stock | USD 0.0002 0.00 0.00% |
Evolutionary Genomics seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of Evolutionary Genomics from reviewing the firm fundamentals such as Current Valuation of 9.18 M, shares owned by insiders of 32.60 %, and Price To Earning of (3.79) X as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Evolutionary Genomics' price fluctuation is very steady at this time. Calculation of the real value of Evolutionary Genomics is based on 3 months time horizon. Increasing Evolutionary Genomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Evolutionary pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Evolutionary Genomics. Since Evolutionary Genomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Evolutionary Pink Sheet. However, Evolutionary Genomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.0E-4 | Real 1.68E-4 | Hype 2.0E-4 | Naive 2.0E-4 |
The intrinsic value of Evolutionary Genomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Evolutionary Genomics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Evolutionary Genomics helps investors to forecast how Evolutionary pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Evolutionary Genomics more accurately as focusing exclusively on Evolutionary Genomics' fundamentals will not take into account other important factors: Evolutionary Genomics Total Value Analysis
Evolutionary Genomics is currently forecasted to have valuation of 9.18 M with market capitalization of 4.66 M, debt of 3.74 M, and cash on hands of 897.78 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Evolutionary Genomics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
9.18 M | 4.66 M | 3.74 M | 897.78 K |
Evolutionary Genomics Asset Utilization
One of the ways to look at asset utilization of Evolutionary is to check how much profit was generated for every dollar of assets it reports. Evolutionary Genomics shows a negative utilization of assets of -0.45 percent, losing $0.004538 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Evolutionary Genomics shows how discouraging it operates for each dollar spent on its assets.Evolutionary Genomics Ownership Allocation
Evolutionary Genomics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Evolutionary Genomics Profitability Analysis
Net Loss for the year was (2.79 M) with loss before overhead, payroll, taxes, and interest of (1.23 M).About Evolutionary Genomics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Evolutionary Genomics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Evolutionary Genomics based exclusively on its fundamental and basic technical indicators. By analyzing Evolutionary Genomics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Evolutionary Genomics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Evolutionary Genomics. We calculate exposure to Evolutionary Genomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Evolutionary Genomics's related companies.Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. Evolutionary Genomics, Inc. was incorporated in 1990 and is based in Castle Rock, Colorado. Evolutionary Genomics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.
8 Steps to conduct Evolutionary Genomics' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Evolutionary Genomics' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Evolutionary Genomics' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Evolutionary Genomics' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Evolutionary Genomics' revenue streams: Identify Evolutionary Genomics' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Evolutionary Genomics' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Evolutionary Genomics' growth potential: Evaluate Evolutionary Genomics' management, business model, and growth potential.
- Determine Evolutionary Genomics' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Evolutionary Genomics' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Evolutionary Genomics Growth Indicators
Investing in growth stocks can be very risky. If the company such as Evolutionary Genomics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 5.9 M | |
| Retained Earnings | -17.9 M |
Other Information on Investing in Evolutionary Pink Sheet
Evolutionary Genomics financial ratios help investors to determine whether Evolutionary Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evolutionary with respect to the benefits of owning Evolutionary Genomics security.